Position in DNLI
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,629,638
+$718,202 QoQ
Shares Held
102,241
+2.7% QoQ
Ownership
0.064%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#85
of 290 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Integrated Wealth Concepts LLC holds $51,111,337 across 302 Biotechnology names. DNLI ranks #5 (5.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
152,216 | $8,709,799 | |
| 2 | INVA |
Innoviva, Inc.
|
350,575 | $7,961,558 | |
| 3 | EXEL |
Exelixis, Inc.
|
69,926 | $3,804,673 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,994 | $3,474,129 | |
| 5 | DNLI |
Denali Therapeutics Inc.
This page
|
102,241 | $2,629,638 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,692 | $2,014,492 | |
| 7 | INCY |
Incyte Corp
|
17,318 | $1,963,168 | |
| 8 | TLX |
Telix Pharmaceuticals Ltd
|
164,397 | $1,895,497 |
All Filings in DNLI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,629,638 | 102,241 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $1,911,436 | 99,554 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $1,561,548 | 94,582 | Shares | Other | 2026-02-13 | |
| 2025-09-30 | $1,322,394 | 91,074 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $1,343,683 | 96,046 | Shares | Other | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||